Results 21 to 30 of about 3,972 (148)
Diagnostic Pathology, 2023 Background Among the three NTRK genes, NTRK2 possesses a tremendous structural complexity and involves tumorigenesis of several types of tumors. To date, only STRN and RBPMS are identified in the fusion with NTRK2 in adult soft tissue tumors.
Ruihe Lin +5 more
doaj +1 more source
Frontiers in Bioengineering and Biotechnology, 2023 Larotrectinib (Lar) is an orally administered tropomyosin receptor kinase (Trk) inhibitor with broad-spectrum antitumor activity that is available in clinical dosage forms as capsules and oral solutions.
Lu Gan +5 more
doaj +1 more source
Clinical Case Reports, 2021 Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer.
Fabián Pitoia
doaj +1 more source
Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report
Case Reports in Oncology, 2021 While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion ...
Tyler Lanman +4 more
doaj +1 more source
Cancer Research, Statistics, and Treatment, 2021 Lung cancer diagnostics and therapeutics have witnessed a paradigm shift in the last decade because of the discovery of targetable biomarkers and rapid approvals of the corresponding targeted therapies.
Ullas Batra +2 more
doaj +1 more source
Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer. [PDF]
, 2023 In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these ...
Haefliger, Simon +4 more
core +2 more sources
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
Current Oncology, 2021 Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault +10 more
doaj +1 more source
NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers
Journal of Contemporary Medicine, 2022 Neurotrophic tyrosine receptor kinase (NTRK) gene rearrangements have been recently identified and developed as one of the biomarkers that have been utilized as new targets for cancer therapy.
Emel Ünal +2 more
doaj +1 more source
Frontiers in Oncology, 2023 Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies.
Emanuela Palmerini +17 more
doaj +1 more source
Molecular Landscape in Infant High-Grade Gliomas: A Single Center Experience
Diagnostics, 2022 High-grade gliomas (HGG) represent about 15% of all pediatric brain tumors, with a dismal prognosis and survival rates ranging from 15 to 35%. Approximately 10–12% of pediatric HGGs (pHGG) occur in children younger than five years of age at diagnosis ...
Valentina Di Ruscio +11 more
doaj +1 more source